Canaccord analyst Susan Anderson lowered the firm’s price target on Niagen Bioscience (NAGE) to $13 from $14 and keeps a Buy rating on the shares. The firm updatedits model following Q4 results where demand remains strong for its core business and potential upside is seen with its injectable business.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience: Tru Niagen‑Driven Beat, Durable Double‑Digit Growth Outlook, and FDA Litigation Upside Support Buy Rating
- Niagen Bioscience Reports Strong 2025 Results, Strategic Shift
- Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M
- Niagen Bioscience up 39% at $6.88 after Q4 results and guidance
- Niagen Bioscience reports Q4 EPS 5c, consensus 2c